I spent a few minutes today on Amazon, to check on reports that some Kindle titles now have text to speech disabled. Among the authors who are “turning off” text to speech in Kindle editions of books are President Obama, Vice President Biden, Toni Morrison, the Pope, Stephen King, Maya Angelou, Mother Teresa, Isaac Asimov, Tom Brokaw, P.D. James, Robert B. Reich, George Will and Ann Coulter, to mention a few.
KEI has a page that summarizes the minimum terms of protection for copyright and related rights in multilateral treaties. The most binding constraints are those included in the WTO TRIPS Agreement. Those constraints are as follows:
Most literary and artistic works protected by copyright under the Berne would have a minimum copyright term calculated on the basis of the life of the author plus 50 years.
In efforts to introduce the topic of innovation inducement prizes into the discussions about drug development, there are inevitably questions about the relationship between grants and prizes.
In some cases, prizes are being offered as a reform of “pull” mechanisms, and can usefully be compared to the grant of a marketing monopoly, which is the primary pull mechanism used today. In this context, a question is, should drug or vaccine developers be rewarded with monopolies or cash? And if cash, where does the money come from, and how much money is given to a particular project?
MICROSOFT CORPORATION, FORM 10-Q For the Quarter Ended March 31, 2009
Item 1A. Risk Factors
Our operations and financial results are subject to various risks and uncertainties, including those described below, that could adversely affect our business, financial condition, results of operations, cash flows, and the trading price of our common stock.
These were my tweets yesterday from the Fordham/Cambridge IPR event:
# Fordham event in Cambridge, UK. Michael Keplinger from WIPO said treaty for reading disabled “would take years and not solve the problem”
# At Fordham/Cambridge IP event, Luc Devigne of DG Trade says ACTA membership will be “enlarged,” become standard for developing countries.
On April 8, 2009, the FDA announced it had awarded Novartis a one-time priority review voucher (PRV) to use towards a future new drug application, for Coartem, a malaria drug. While the PRV was designed as an incentive to develop new drugs, Coartem was developed and put on the market outside the United States years before the PRV legislation was proposed. Continue Reading
I am in Montreal right now, and missed the Right Rights Coalition demonstration at the Authors Guild. Manon, Judit and Malini from our office are in NYC at the demonstration, and said it was incredibly moving. Several people at the protest sent reports by tweeter. The most complete was probably Abraham Lloyd. This was his account, with the Tweets organized from his first to last.